focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
https://www.sciencedirect.com/science/article/pii/S1568997220301294
There is a second report: Type I Interferons Are Essential in Controlling Neurotropic Coronavirus Infection Irrespective of Functional CD8 T Cells by Journal of Virology at the American Society of Microbiology 2007.
Key points:
These data demonstrate a critical direct antiviral role of IFN-I in controlling virus dissemination within the CNS, even in the presence of potent cellular immune responses. By limiting early viral replication and tropism, IFN-I controls the balance of viral replication and immune control in favor of CD8 T-cell-mediated protective functions.
Report: Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions by Department of Internal Medicine, Lyon University Hospital, Lyon, France 4th May 2020.
This is a long report so it will take some time to digest for those interested. But it has some very positive analysis regarding Interferon-beta treatment in SARS-CoV-2. I have selected highlighted some of the key points below. The report highlights that interferon INHALATION can lower the infection rate - supporting the SNG001 nebuliser method. Very interesting.
IFN-a and IFN-ß have emerged as potentially effective drugs against SARS-CoV-2.
IFN-a and -ß have very systematically demonstrated robust efficacy against coronaviruses
IFN-ß1b and IFN-ß1a are the most potent subtypes for SARS-CoV inhibition (probably even more for SARS-CoV-2)
type-I IFN must be administered as soon as possible after infection (ideally before symptom onset)
IFN-a inhalation can lower SARS-CoV-2 infection rate and serve in prophylaxis or treatment
In the very early stages of the disease, treatment should focus on reducing viral load either by specific antivirals or by stimulating type-I IFN
The report is interesting, and it is clear that medical institutions are crying out for robust data from clinical trials that are well controlled and double-blind.
Well all those people predicting £1 opening today should hang their heads in shame. I thought this would happen yesterday, I tried to inject a dose of reality to this board and call out the pumpers , but apparently that's boring and I should shut up. I get that predicting £1 is nice to hear, but it just hypes things beyond reality. The Panorama programme was good media coverage, but it was never going to skyrocket this share, a nice steady rise would have been perfect, but instead people are dumping shares and the reality of 4-8 weeks until results sinks in, people need to level up a bit and stop posting £1 predictions. Go ahead and filter me if you wish, but perhaps you should be filtering the people who predicted £1 rather than the person who called out them out as liars and told you this would happen.
You may think I am boring, deramping or just plain negative, but I am calling out the obvious lies and deception on the board. Not because I want to get in cheaper, but because I want to protect my investment against repetitive ramping and crashing. It happens with AIM shares all the time, and over time it erodes the credibility of a share. We’ve got at least 4 weeks to go, or 8 if you believe the BBC. You can filter me if you like, but I’d rather know the truth if a patient has either ‘miraculously recovered’ or just been admitted and having either her first or second dose.
The panorama interview was good, but again tainted by the constant hyping and ramping. It does no good for the credibility of people who post, they are either deluded or do not understand the trial.
The patient was admitted the day before filming, therefore given the time taken to go through the waiver, explain the trial and prepare the medication this was likely to be the first dose on camera. She had not 'miraculously recovered'. This is just basic stuff, if you know the company you are invested in.
It's almost become cult like this board, crucify the non-believers! Thing is I do believe in the company and the drug, just not the posters who claim it's going to be £1 tomorrow, and then set up the trolls for a day of deramping to sow seeds of doubt in investors minds. I'd rather counteract that and call out the BS for what it is. We have until the end of June, posting about daily share price rises and predictions of meteoric rises following a brief report on Panorama is just setting everyone up for a day of disappointment and gives opportunities to derampers.
I mean the last few comments just go to prove my point, there is no point posting minute by minute accounts of the share price when it rises a percentage point. I know there's some comfort in enjoying a rise, but it just become sentiment driven rather than evidence or research driven. I'd rather people post about the reality for the next few weeks ahead so that we don't have an endless cycle of pump and dump until result day. I'm laying it out, I think the share price will drift down over the next few weeks, largely because of people posting rubbish like this. Now I don't think that's a bad thing, if you're in for the long haul then short-term ups and downs don't matter. But i'd rather the board wasn't turned into a pat on the back self-appreciation society posting minute by minute accounts of the share-price volatility. People should expect a retrace, and they shouldn't be alarmed by it. Our eyes should be on the end of June, not day to day price movements and the pumping that goes along with it.
I just get tired of the constant ramping and hyping, it drowns out anything genuinely useful and then people get defensive when someone points out reality. I will happily come back tomorrow and eat my words, but this won't be at a £1 to buy in, that's just silly. People will be disappointed, then the trolls start and people are scared out of investment.
I sincerely hope that there is a steady stream of coverage about this and the media don't get bored, but my hunch is that things will go fairly quiet, the media circus will find another 'wonder drug' to talk about and it will come back around in a few weeks when our trial results are due. We all have a very personal and financial interest in this company, those in the media don't. That's why i'm cautious.
I think people are missing my point, i'm not complaining about the coverage, that is a good thing. Just the way the programme is being hyped on this board. There are a lot of people new to sharedealing who have arrived here recently, seeing an opportunity and a chance to invest in a stock that might help beat the virus. Rather than just seeing it as a positive and left at that, it is hyped and pumped by people saying things like 'gap up in the morning', 'you won't get in for under £1 tomorrow morning' etc etc. It's just not true, that's what triggers a sell off as people are disappointed not to see a massive rise and then the reality of sitting on your fingers for 4-8 weeks sinks in.
The way it has been hyped it's almost as if the Panorama programme is solely about SNG001. Publicity is great, and there's nothing wrong about being featured on the programme, just the way it is being hyped. I would rather a steady stream of good stories, rather than a massive hype for a programme and then a sell-off as the inevitable pump and dumpers head off.
I think people need to be a bit cautious about the Panorama programme tonight, I'm worried it is being hyped to something more than it is, and they'll be a sell-off tomorrow when people are underwhelmed. The programme is about all the various treatments and vaccines, not just SNG001. There are many different 'treatments' each one suggesting theirs is best and until we have the data we won't know. There is still a long way to go on this trial and patience is needed, there will be ups and downs inevitably while waiting for the results. Two months is an awful long time in the share-dealing world to wait. Particularly given the amount of worldwide brainpower and investment that is going to find a cure/treatment that works, I don't doubt this will be squeaky bum time and there will be many moments of hovering over the sell button. Whatever happens the company can fall back its core treatment for COPD and asthma sufferers so its not a pure 50/50 win or loose play.
and there's always the risk (or success? depending how you look at it) that someone somewhere in the world comes up with a vaccine/treatment and we are back to our work of COPD treatment. This isn't a 50/50 play, but there will be a sell-off if either the treatment isn't successful or another company develop a working treatment before.
The real take home from the interview was the ramp up of manufacturing for devices and the drug supply chain to enable Synairgen to ramp up to millions of doses. There is a growing body of evidence that shows that people are coming to hospital too late, see the New York Times report by Dr Richard Levitan. If SNG001 proves successful the means of administering by nebuliser makes it ideal for home delivery as a prophylactic to help prevent deterioration into more severe cases. The saving to the health service by keeping people out of hospital and off ventilators is huge! All the pieces are falling into place it seems and i'm excitingly awaiting the results.
"We have started the manufacturing process [devices for delivery of the drug to lungs and more drug products] and we have started to look down the supply chain to ensure we can provide millions of doses to people around the world" WOW!
The Nottingham Biomedical Research Centre have now commenced the SNG001 trial under the direction of Professor Tim Harrison. From the NBRC website:
We have now commenced research into a treatment for patients with confirmed SARS-CoV-2 infection (#COVID19) with Professor Tim Harrison as site principal investigator and managed and delivered by Liz Dark and the asthma team from NRRU.
The research, sponsored by Synairgen Research Limited is a randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection.
The purpose of this research study is to test SNG001 (the study medication). SNG001 is an inhaled drug that contains interferon-ß, an antiviral protein that occurs naturally in the body. Interferon-ß has been given as an injection to thousands of patients for other diseases (such as multiple sclerosis), this trial is about giving SNG001 by inhalation.